Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA0076361033
- Market cap
- 663K
- P/E ratio
- Not available
- Analyst target
- 2.52
- Dividend yield
- Not available
- Beta
- -0.29
About
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Visit company website
5 years, 5 months ago
Aequus Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 21.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.
Aequus Pharmaceuticals Inc's total revenue rose by 66.9% to $619K since the same quarter in the previous year.
Its net income has increased by 61.9% to $-252K since the same quarter in the previous year.
Finally, its free cash flow grew by 81.1% to $-105K since the same quarter in the previous year.
Based on the above factors, Aequus Pharmaceuticals Inc gets an overall score of 4/5.